theraclone11

Theraclone Sciences raises $10M

Theraclone Sciences, a Seattle biotechnology company that’s developing a method to rapidly identify disease-fighting antivbodies, has attracted $10.6 million. Investors in the deal include ARCH Venture Partners, Canaan Partners, MPM Capital, Healthcare Ventures, Alexandria Real Estate Equities, Amgen Ventures and Zenyaku Kogyo “The anticipated near-term initiation of Theraclone’s first clinical trial and our discovery collaboration with Pfizer earlier… Read More